Thermo Fisher Scientific Inc. (NYSE: TMO) is enhancing its growth strategy by collaborating with OpenAI to integrate artificial intelligence (AI) in critical business areas. This partnership aims to accelerate drug development, streamline clinical trials, and enable faster delivery of medicines to patients, thereby reducing costs for customers. Key implementations include embedding OpenAI APIs into product development and service delivery, particularly within Thermo Fisher’s PPD™ clinical research business. The collaboration will also leverage AI to quickly identify less promising therapies, reallocating resources toward more viable options. Additionally, the integration of AI into Thermo Fisher’s Accelerator™ Drug Development solution enhances efficiency across all phases of clinical research. According to Marc Casper, CEO of Thermo Fisher, this partnership aims to make scientific advancements more impactful for customers and society. With annual revenues exceeding $40 billion, Thermo Fisher remains committed to improving global health and safety through innovative technologies and services.
Source link
Share
Read more